v3.25.0.1
SHAREHOLDERS' EQUITY (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Share-based Payment Arrangement [Abstract]    
Schedule of employee options activity
 
 
Number
   
Weighted
average
exercise
price
   
Weighted
average
remaining
contractual
life (years)
   
Aggregate
intrinsic
value (in
thousands)
 
Options outstanding as of December 31, 2023
   
4,723
   
$
259.73
     
4.39
   
$
-
 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
-
     
-
     
-
     
-
 
Forfeited
   
-
     
-
     
-
     
-
 
Options outstanding as of September 30, 2024
   
4,723
   
$
259.73
     
3.62
   
$
-
 
 
                               
Options exercisable as of September 30, 2024
   
4,723
   
$
259.73
     
3.62
   
$
-
 
 
 
Number
   
Weighted
average
exercise
price
   
Weighted
average
remaining
contractual
life (years)
   
Aggregate
intrinsic
value (in
thousands)
 
Options outstanding at the beginning of the year
   
43,994
   
$
41.27
     
4.39
   
$
-
 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
-
     
-
     
-
     
-
 
Forfeited
   
(10,823
)
   
52.78
     
-
     
-
 
 
                               
Options outstanding at the end of the year
   
33,171
   
$
37.51
     
4.39
   
$
-
 
 
                               
Options exercisable at the end of the year
   
33,171
   
$
37.51
     
4.39
   
$
-
 
Schedule of employee RSUs activity
 
 
Number of
shares
underlying
outstanding
RSUs
   
Weighted-
average
grant date
fair value
 
Unvested RSUs as of December 31, 2023
   
538,885
   
$
6.07
 
Granted
   
14,740
     
4.80
 
Vested
   
(218,493
)
   
6.56
 
Forfeited
   
(3,413
)
   
6.86
 
Unvested RSUs as of September 30, 2024
   
331,719
   
$
5.68
 
 
 
Number of
shares
underlying
outstanding
RSUs
   
Weighted-
average
grant date
fair value
 
Unvested RSUs at the beginning of the year
   
2,755,057
     
1.16
 
Granted
   
2,258,370
     
0.66
 
Vested
   
(1,109,200
)
   
1.14
 
Forfeited
   
(131,813
)
   
1.13
 
 
               
Unvested RSUs at the end of the year
   
3,772,414
     
0.87
 
Schedule of options and RSUs outstanding
     
Weighted
average
remaining
contractual
life (years) (1)
   
Options outstanding and
exercisable as of
September 30, 2024
   
Weighted
average
remaining
contractual
life (years) (1)
 
Range of exercise price
   
Options and RSUs
outstanding as of
September 30, 2024
             
             
             
RSUs only
     
331,719
     
-
     
-
     
-
 
$37.6
     
1,774
     
4.49
     
1,774
     
4.49
 
$178.5 - $236.3
     
1,845
     
3.59
     
1,845
     
3.59
 
$350 - $367.5
     
887
     
2.65
     
887
     
2.65
 
$1,277.5 - $3,634.8
     
217
     
0.63
     
217
     
0.63
 
       
336,442
     
3.62
     
4,723
     
3.62
 
 
Range of exercise price
 
Options and
RSUs
Outstanding
as of
December 31,
2023
 
 
Weighted
average
remaining
contractual
life
(years) (1)
 
 
Options
Exercisable
as of
December 31,
2023
 
 
Weighted
average
remaining
contractual
life
(years) (1)
 
RSUs only
 
 
3,772,414
 
 
 
-
 
 
 
-
 
 
 
-
 
$5.37 
 
 
12,425
 
 
 
5.24
 
 
 
12,425
 
 
 
5.24
 
$20.42- $33.75 
 
 
12,943
 
 
 
4.35
 
 
 
12,943
 
 
 
4.35
 
$50-$52.5 
 
 
6,230
 
 
 
3.46
 
 
 
6,230
 
 
 
3.46
 
$182.5-$524.25 
 
 
1,573
 
 
 
1.65
 
 
 
1,573
 
 
 
1.65
 
 
 
 
3,805,585
 
 
 
4.39
 
 
 
33,171
 
 
 
4.39
 
Schedule of warrants outstanding and exercisable
Issuance date
 
Warrants
outstanding
   
Exercise price
per warrant
   
Warrants
outstanding
and
exercisable
 
Contractual
term
 
 
(number)
         
(number)
 
 
December 31, 2015 (1)
   
681
   
$
52.50
     
681
 
See footnote (1)
December 28, 2016 (2)
   
272
   
$
52.50
     
272
 
See footnote (1)
April 5, 2019 (3)
   
58,350
   
$
35.98
     
58,350
 
October 7, 2024
June 12, 2019 (4)
   
59,523
   
$
42.00
     
59,523
 
December 12, 2024
February 10, 2020 (5)
   
4,054
   
$
8.75
     
4,054
 
February 10, 2025
February 10, 2020 (6)
   
15,120
   
$
10.94
     
15,120
 
February 10, 2025
July 6, 2020 (7)
   
64,099
   
$
12.32
     
64,099
 
January 2, 2026
July 6, 2020 (8)
   
42,326
   
$
15.95
     
42,326
 
January 2, 2026
December 8, 2020 (9)
   
83,821
   
$
9.38
     
83,821
 
June 8, 2026
December 8, 2020 (10)
   
15,543
   
$
12.55
     
15,543
 
June 8, 2026
February 26, 2021 (11)    
   
780,095
   
$
25.20
     
780,095
 
August 26, 2026
February 26, 2021 (12)
   
93,612
   
$
32.05
     
93,612
 
August 26, 2026
September 29, 2021 (13)
   
1,143,821
   
$
14.00
     
1,143,821
 
March 29, 2027
September 29, 2021 (14)
   
137,257
   
$
17.81
     
137,257
 
September 27, 2026
 
   
2,498,574
             
2,498,574
 
 
 
  (1)
Represents warrants for ordinary shares issuable upon an exercise price of $52.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2024.
 
  (2)
Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
 
  (3)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.
 
  (4)
Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.
 
  (5)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of September 30, 2024, 534,300 warrants were exercised for a total consideration of $4,675,125.
 
During the nine months ended September 30, 2024, no warrants were exercised.
 
  (6)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of September 30, 2024, 32,880 warrants were exercised for a total consideration of $359,625.
 
During the nine months ended September 30, 2024, no warrants were exercised.
 
  (7)
Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of September 30, 2024, 288,634 warrants were exercised for a total consideration of $3,556,976.
 
During the nine months that ended September 30, 2024, no warrants were exercised.
 
  (8)
Represents warrants that were issued to the placement agent as compensation for his role in the Company’s July 2020 registered direct offering.
 
  (9)
Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of September 30, 2024, 514,010 warrants were exercised for a total consideration of $4,821,416.
 
During the nine months that ended September 30, 2024, no warrants were exercised.
 
  (10)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of September 30, 2024, 32,283 warrants were exercised for a total consideration of $405,003.
 
During the nine months that ended September 30, 2024, no warrants were exercised.
 
  (11)
Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021.
 
  (12)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.
 
  (13)
Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021.
 
  (14)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.
Issuance date
 
Warrants
outstanding
   
Exercise price
per warrant
   
Warrants
outstanding
and
exercisable
 
Contractual
term
 
 
(number)
         
(number)
 
 
December 31, 2015 (1)
   
4,771
   
$
7.500
     
4,771
 
See footnote (1)
December 28, 2016 (2)
   
1,908
   
$
7.500
     
1,908
 
See footnote (1)
February 25, 2019 (5)
   
45,600
   
$
7.187
     
45,600
 
February 21, 2024
April 5, 2019 (6)
   
408,457
   
$
5.140
     
408,457
 
October 7, 2024
April 5, 2019 (7)
   
49,015
   
$
6.503
     
49,015
 
April 3, 2024
June 5, 2019, and June 6, 2019 (8)
   
1,464,665
   
$
7.500
     
1,464,665
 
June 5, 2024
June 5, 2019 (9)
   
87,880
   
$
9.375
     
87,880
 
June 5, 2024
June 12, 2019 (10)
   
416,667
   
$
6.000
     
416,667
 
December 12, 2024
June 10, 2019 (11)
   
50,000
   
$
7.500
     
50,000
 
June 10, 2024
February 10, 2020 (12)
   
28,400
   
$
1.250
     
28,400
 
February 10, 2025
February 10, 2020 (13)
   
105,840
   
$
1.563
     
105,840
 
February 10, 2025
July 6, 2020 (14)
   
448,698
   
$
1.760
     
448,698
 
January 2, 2026
July 6, 2020 (15)
   
296,297
   
$
2.278
     
296,297
 
January 2, 2026
December 8, 2020 (16)
   
586,760
   
$
1.340
     
586,760
 
June 8, 2026
December 8, 2020 (17)
   
108,806
   
$
1.792
     
108,806
 
June 8, 2026
February 26, 2021 (18)
   
5,460,751
   
$
3.600
     
5,460,751
 
August 26, 2026
February 26, 2021 (19)
   
655,290
   
$
4.578
     
655,290
 
August 26, 2026
September 29, 2021 (20)
   
8,006,759
   
$
2.000
     
8,006,759
 
March 29, 2027
September 29, 2021 (21)
   
960,811
   
$
2.544
     
960,811
 
September 27, 2026
 
   
19,187,375
             
19,187,375
 
 
Schedule of non-cash share-based compensation expense
 
 
Nine Months Ended September 30,
 
   
2024
   
2023
 
Cost of revenues
 
$
12
   
$
5
 
Research and development, net
   
130
     
112
 
Sales and marketing
   
309
     
270
 
General and administrative
   
596
     
568
 
Total
 
$
1,047
   
$
955
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Cost of revenue
 
$
9
   
$
16
   
$
10
 
Research and development, net
   
157
     
94
     
55
 
Sales and marketing
   
381
     
250
     
171
 
General and administrative
   
781
     
633
     
597
 
 
                       
Total
 
$
1,328
   
$
993
   
$
833